Supporting this notion, recent clinical studies demonstrate that the presence of NRF2 activation or KEAP1 mutation in lung cancer is highly predictive of the unresponsiveness to immunotherapy 31, 78. This evidence concerns the gene NFE2L2 and lung carcinoma.